Rainier Acquisition Corporation prices $75 million IPO for life sciences SPAC
- Rainier Acquisition Corporation priced its IPO of 7.5 million units at $10.00 each
- Gross proceeds total $75,000,000 before underwriting discounts and offering expenses
- Each unit includes one Class A ordinary share and one-quarter of a redeemable warrant
- Warrants allow purchase of shares at $11.50; units trade as RNAQU on Nasdaq
- Chardan granted a 45-day over-allotment option for up to 1,125,000 additional units
*this image is generated using AI for illustrative purposes only.
Rainier Acquisition Corporation priced its initial public offering of 7,500,000 units at $10.00 per unit, generating gross proceeds of $75,000,000 before expenses. The special purpose acquisition company aims to merge with businesses in the global life sciences sector.
The offering consists of one Class A ordinary share and one-quarter of one redeemable warrant per unit. Each whole warrant entitles the holder to purchase one Class A ordinary share at $11.50. The units are expected to list on The Nasdaq Capital Market under the ticker symbol RNAQU beginning August 27, 2026.
Capital Structure and Trading Details
Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants will trade under the symbols RNAQ and RNAQW, respectively. No fractional warrants will be issued upon separation of the units; only whole warrants will trade.
| Component | Detail |
|---|---|
| Units Offered | 7,500,000 |
| Price Per Unit | $10.00 |
| Gross Proceeds | $75,000,000 |
| Warrant Exercise Price | $11.50 |
| Ticker Symbols | RNAQU (Units), RNAQ (Shares), RNAQW (Warrants) |
Chardan acted as the sole book-running manager for the offering. The Company granted the underwriter a 45-day option to purchase up to an additional 1,125,000 units at the initial public offering price to cover over-allotments. The offering is expected to close on August 28, 2026, subject to customary closing conditions.
Strategic Focus and Management
The Company intends to focus its search on the global life sciences industries, including therapeutics, diagnostics, genomics, precision medicine, life science tools, research services, biomanufacturing, and related subsectors. Its efforts to identify a prospective target business will not be limited to any particular industry or geographical region.
The management team is led by Gbola Amusa, MD, CFA, Chief Executive Officer, and Guy Barudin, Chief Financial Officer.
Regulatory Filings
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 26, 2026. The offering is being made only by means of a prospectus, copies of which may be obtained from Chardan.
How does Rainier Acquisition's $75 million raise compare to recent SPAC IPOs in the life sciences sector, and what does this indicate about current investor appetite for biotech deals?
Given the specific focus on genomics and precision medicine, which emerging therapeutic trends might make certain targets more attractive to Rainier's management team?
What is the likelihood of Chardan exercising the 45-day over-allotment option to purchase an additional 1.125 million units, and how would this impact the final capital available for a merger?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
